Table 1.

Urine volume (V), free-water clearance (C_H20), glomerular filtation rate (GFR), and urinary electrolyte excretion (U_NaV, U_KV,U_ClV)before (–2–0 h) and after oral administration of 1, 5, or 10 mg asimadoline as compared with placebo in each group of eight healthy subjects in the absence (0–2 h) and presence of 2.5% saline infusion (2–4 h).*P < 0.05;**P < 0.01.

Parameters	Collection interval	Placebo	1 mg asimadoline	Placebo	5 mg asimadoline	Placebo	10 mg asimadoline
V
(ml min−1)	−2–0 h	7.2 ± 1.6	6.2 ± 1.3	8.7 ± 2.1	7.6 ± 1.0	7.4 ± 2.3	8.0 ± 2.0
	0–2 h	2.8 ± 0.8	3.3 ± 0.6	3.3 ± 1.4	5.6 ± 1.4**	3.2 ± 1.6	5.5 ± 2.2**
	2–4 h (2.5% NaCl i.v.)	2.8 ± 0.8	3.0 ± 0.9	2.7 ± 0.7	3.0 ± 0.8	3.1 ± 1.1	3.9 ± 1.4
CH2O
(ml min−1)	−2–0 h	5.3 ± 1.8	4.7 ± 2.2	5.7 ± 1.2	5.0 ± 0.9	4.1 ± 1.9	5.4 ± 1.2
	0–2 h	0.5 ± 1.1	1.6 ± 2.2	−0.2 ± 1.0	2.0 ± 1.6**	0.6 ± 1.6	3.0 ± 1.7**
	2–4 h (2.5% NaCl i.v.)	−2.3 ± 0.7	−2.1 ± 1.2	−2.4 ± 0.8	−2.5 ± 0.5	−2.5 ± 0.7	−1.7 ± 1.1**
GFR
(ml min−1)	−2–0 h	113 ± 10	109 ± 23	122 ± 19	105 ± 11	123 ± 27	116 ± 12
	0–2 h	118 ± 8	126 ± 18	122 ± 15	124 ± 8	120 ± 21	117 ± 23
	2–4 h (2.5% NaCl i.v.)	140 ± 18	140 ± 23	136 ± 23	138 ± 15	133 ± 29	133 ± 33
UNaV
(µmol min−1)	−2–0 h	146 ± 40	131 ± 65	156 ± 45	143 ± 20	135 ± 47	117 ± 32
	0–2 h	193 ± 32	171 ± 54	195 ± 43	213 ± 43	178 ± 47	138 ± 39
	2–4 h (2.5% NaCl i.v.)	581 ± 163	642 ± 226	619 ± 211	625 ± 157	647 ± 267	623 ± 320
UKV
(µmol min−1)	−2–0 h	91 ± 22	64 ± 12	76 ± 32	70 ± 22	62 ± 28	45 ± 11
	0–2 h	92 ± 11	89 ± 17	89 ± 30	102 ± 38	72 ± 17	68 ± 21
	2–4 h (2.5% NaCl i.v.)	108 ± 11	126 ± 40	111 ± 35	116 ± 13	115 ± 41	108 ± 46
UClV
(µmol min−1)	−2–0 h	129 ± 54	125 ± 55	147 ± 45	123 ± 34	121 ± 48	105 ± 31
	0–2 h	185 ± 47	175 ± 54	178 ± 48	194 ± 45	226 ± 121	121 ± 44
	2–4 h (2.5% NaCl i.v.)	48 ± 245	623 ± 278	675 ± 228	697 ± 178	698 ± 270	643 ± 331